What we offer
Preclinical models of hematological malignancies
MIMO brings together know-how, technology and animal models with the mission of providing preclinical services to academic and pharma partners in multiple myeloma (MM), lymphoma, and other related fields. With a highly qualified scientific and management team, MIMO has launched an ambitious program to develop newly designed, proprietary preclinical models of genetically diverse MM with multiple humanized targets. These models faithfully recapitulate clinical conditions that are in need of more effective therapies, such as high-risk MM with TP53 loss, genetic instability, or t(4;14), VRD and BCMA-targeted refractory states, extramedullary disease, and light-chain amyloidosis.
MIMO is also generating patient-derived xenograft (PDX) models from MM patient samples engrafted into IL6-secreting immunodeficient mice, reconstituted with a human immune system. The goal of the humanized PDX is to directly study clinical immunotherapy agents that cannot be tested in other experimental systems.
Additionally, MIMO is expanding the generation of humanized mouse and PDX models for the principal B-cell lymphoma subtypes (DLBCL, FCL, LPL/WM, MZL/MALT lymphoma), as well as for acute myeloid leukemia (AML).
What we offer at Mimo Biosciences
THE NEXT LEVEL OF PRECLINICAL RESEARCH
- Scientific research agreements using unique models of human-like cancers
- Specialized in hematological malignancies, primarily multiple myeloma and B-cell lymphomas; other tumor types under development
- Project design customized to client needs based on scientific and clinical partnership
- Scientific supervision throughout the project, allowing dynamic modifications
UNPRECEDENTED VARIETY OF COMPLEMENTARY CANCER MODELS
- Standard-risk myeloma with t(11;14)
- High-risk disease with TP53 loss, 1q amplification, or t(4;14)
- Super MNC (MYC/NF-κB/cγ1) mice
- MGUS and SMM models
- Extramedullary myeloma
- VRD refractory myeloma
- MM immune subtypes
- Light-chain amyloidosis (1)
Genetically engineered, fully immunocompetent models of B-cell lymphoma subtypes:
- Indolent MZL/MALT lymphoma, LPL, and follicular lymphoma
- DLBCL-like models of ABC and GCB subtypes
- MCD, A53 and EZH DLBCL genetic subclasses
- Doble-hit MYC/BCL2 lymphomas
- DLBCL with inflamed and depleted immune microenvironments
Syngeneic models with immortalized cell lines established from genetically heterogeneous primary myeloma and lymphoma samples injected into immunocompetent C57BL/6 mice.
(1) Coming soon
MAKING OUR MODELS MORE HUMAN
Humanization of therapeutic targets in tumor and immune cells:
- BCMA, GPRC5D and CD38 in myeloma
- CD20 and CD19 in lymphomas
- CD3ε, CD28 and 4-1-BB in T lymphocytes
- CRBN in tumor and immune cells
Humanization of the immune system in patient-derived xenografts of acute myeloid leukemia, B-cell lymphomas, and multiple myeloma
- NSG-huIL6 mice
- NSG-MHC-I/II-/- mice
New models for other hematologic malignancies and solid tumors (3)
(3) Ask availability of additional models and therapeutic targets.
IMMUNOTHERAPY PLATFORMS FOR PERSONALIZED MEDICINE
Our models allow in vivo testing of chemo- and radiotherapy, targeted agents and immunotherapy combinations:
- Monoclonal antibodies for CD38, SLAMF7 (myeloma) and CD20 (lymphoma)
- Bi-specific antibodies targeting tumor cells (BCMA, GPRC5D, CD38, CD19, CD20) and immune cells (CD3ε, CD28, 4-1-BB) (4)
- Project design customized to client needs based on scientific and clinical partnership
- Chimeric antigenic receptor (CAR) T cells for myeloma, lymphomas and leukemias
(4) Ask about additional targets, antibody combinations, and tri-specific antibody testing.
EFFICACY AND TOXICITY DRUG TESTING IN PRECLINICAL MODELS
Preclinical therapy trials in syngeneic, transgenic, humanized, and/or PDX models depending on client´s needs:
- Test of 2 to 4 drugs in monotherapy or combined, include 12-15 mice per cohort
- In vivo monitorization of therapy responses
- Myeloma: sequential quantification of serum Igs, circulating tumor cells (CTCs), BM MM cells by tibial aspirates, micro-PET, and survival
- Lymphomas: CTC quantification, micro-CT and/or micro-PET, and survival
- Therapeutic results in 3 to 6 months
DECIPHERING MECHANISMS OF DRUG RESPONSE AND RESISTANCE
A wide range of services and analyses adapted to mouse and human samples:
- Multiparametric flow cytometry and FACS
- Histopathological and immunohistochemistry studies
- RNA and genome sequencing of FACS-sorted subpopulations
- Single-cell RNA sequencing of tumor and immune cells
- BCR and TCR sequencing for clonal analyses
- Computational analyses of sequencing data
Contact form
Fill out the form below and we will contact you as soon as possible!